Mindstate Design Labs
Mindstate Design Labs creates pharmaceutical forms of therapeutically valuable emotions by mapping and modulating the molecular biology of emotional, cognitive, and perceptual states. It uses the Osmanthus ensemble—advanced machine learning models including large language models and Bayesian neural networks—to synthesize large datasets of psychoactive pharmacology, subjective phenomenology, and biochemical receptor profiles to identify neurotransmitter receptor combinations that produce specific mental states. The company is a clinical-stage AI neuroengineering and drug development firm; its lead asset, MSD-001, is in human trials and is designed to be rapid-acting and to enable emotional and cognitive flexibility without producing hallucinations. Mindstate also offers its Osmanthus platform as a tool for biotechnology and pharmaceutical partners to design novel psychoactive drug classes and combination products targeting psychiatric indications.
Mindstate Design Labs
Mindstate Design Labs creates pharmaceutical forms of therapeutically valuable emotions by mapping and modulating the molecular biology of emotional, cognitive, and perceptual states. It uses the Osmanthus ensemble—advanced machine learning models including large language models and Bayesian neural networks—to synthesize large datasets of psychoactive pharmacology, subjective phenomenology, and biochemical receptor profiles to identify neurotransmitter receptor combinations that produce specific mental states. The company is a clinical-stage AI neuroengineering and drug development firm; its lead asset, MSD-001, is in human trials and is designed to be rapid-acting and to enable emotional and cognitive flexibility without producing hallucinations. Mindstate also offers its Osmanthus platform as a tool for biotechnology and pharmaceutical partners to design novel psychoactive drug classes and combination products targeting psychiatric indications.